REVB (Revelation Biosciences) Forward P/E Multiple
Revelation Biosciences is implementing software robots for data analysis to minimize the risks of clinical trial failure and capital shortages. The history of the company's expected P/E ratio visualizes this process, where 0.00 represents the latest metric reading. Growth potential is based on the supply of immunomodulators for patients with kidney disease and respiratory viruses through government insurance programs.
Analytical breakdowns for Revelation Biosciences
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
Total Debt to Equity Ratio Revelation Biosciences|REVB - Long-Term Debt to Capital|Short-Term Debt to Equity Revelation Bio|REVB - Company Aggregate Debt|Debts to Book Capitalization Revelation Biosciences Inc|REVB - Long-Term Debt|Company Short-Term Debt Revelation Biosciences|Quick Ratio revbiosciences.com
- company profitability and valuation multiples indicators:
REVB - Company Net Income|Future Profit Revelation Biosciences|REVB - Price to Earnings Ratio|Forward P/E Multiple Revelation Biosciences Inc|REVB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Revelation Biosciences Corp|REVB - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Revelation Biosciences|REVB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months revbiosciences.com|REVB - Net earnings per one share growth for the current year|Earnings growth forecast for next year Revelation Biosciences
- total revenue and sales volume data:
Summary company analytics:revbiosciences.com
Professional selection of resilient assets is based on comparing market capitalization with projected net income, which allows for the identification of overvaluation. By analyzing the forward P/E ratio of Revelation Biosciences (REVB), an investor assesses the value of the company's future cash flow, which is critical given the high biological risks and intensive R&D pipeline expenditures in the field of immune regulation.
Competitors of Revelation Biosciences (REVB)
Projected Price to Earnings ARGX (Argenx)|BNTX (BioNTech Group) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (Abivax SA)|Market Cap to Projected Earnings admabiologics.com (ADMA)|PTGX - Future Price to Earnings|Immunovant Inc (IMVT) - Projected Price to Earnings|Kiniksa Corp (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols, S.A.|Projected Price to Earnings ADPT|Forward P/E Multiple celldex.com|Future Price to Earnings Aurinia Pharma (AUPH)|BioCryst Pharmaceuticals - Price to Future Earnings Ratio|Forward P/E Multiple VERA (veratx.com)|Dianthus Pharma (DNTH) - Projected Price to Earnings Ratio|PHVS - Future Price to Earnings|ABCL - Forward P/E Multiple|Tourmaline (TRML) - Future Price to Earnings|Precigen - Future Price to Earnings Multiple|PHAR (Pharming Group NV) - Forward P/E Multiple|Forward P/E Multiple Nektar Therapeutics|Future Price to Earnings Upstream Bio Inc (UPB)|Forward P/E Multiple zenasbio.com (ZBIO)|Future Price to Earnings Immunome Corp IMNM|Forward P/E Multiple Gossamer Bio Inc GOSS|KALV - Future Price to Earnings|Future Price to Earnings Multiple SEPN (Septerna Pharma)|PVLA (Pieris Pharmaceuticals) - Projected Price to Earnings|Savara Inc. - Future Price to Earnings Multiple|RIGL (Rigel Pharmaceuticals, Inc.) - Forward P/E Multiple|Future Price to Earnings ANAB|Forward P/E Multiple ATXS|ENGN - Projected Price to Earnings Ratio|Forward P/E Multiple RAPT (rapt.com)|Market Cap to Future Earnings Ratio JBIO (Aerovate)|Aclaris Therapeutics, Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Kyverna Therapeutics Inc.|TLSA: Forward P/E Multiple|CABA - Market Cap to Projected Earnings|VTYX (ventyxbio.com) - Forward P/E Multiple|Projected Price to Earnings Ratio Theratechnologies Inc. THTX|Projected Price to Earnings AVTX (avalotx.com)|Projected Price to Earnings Eledon Pharmaceuticals, Inc. ELDN|Future Price to Earnings Agenus, Inc AGEN|Climb Bio Inc - Future Price to Earnings|Zura Bio Limited - Forward P/E Multiple|Market Cap to Projected Earnings aTyr Pharma, Inc. ATYR|ADAG: Forward P/E Multiple|Price to Expected Earnings Ratio IMA (ImageneBio)|Projected Price to Earnings STTK|EQ: Future Price to Earnings Multiple|Future Price to Earnings Connect Pharma (CNTB)|Forward P/E Multiple Immunic Therapeutics (IMUX)|Forward P/E Multiple ATRA (Atara Biotherapeutics)|Future Price to Earnings Multiple IFRX|XFOR (X4 Pharma) - Projected Price to Earnings Ratio|Future Price to Earnings Multiple ACET (adicetbio.com)|CELU: Forward P/E Multiple|inmunebio.com (INMB) - Forward P/E Multiple|BRNS (Barinthus Biotherapeutics PLC) - Forward P/E Multiple|KZR: Future Price to Earnings Multiple|Future Price to Earnings SAB Biotherapeutics, Inc. (SABS)|AKTX (Akari Therapeutics plc) - Future Price to Earnings Multiple|Future Price to Earnings Enlivex Therapeutics Ltd ENLV|QTTB - Projected Price to Earnings|geovax.com - Forward P/E Multiple|Future Price to Earnings Multiple EDSA (Edesa Biotech Inc)|IBIO: Forward P/E Multiple|Carisma Tx (CARM) - Forward P/E Multiple|XTLB (XTL Biopharmaceuticals) - Forward P/E Multiple|BOLT: Future Price to Earnings Multiple|Projected Price to Earnings HCWB (HCW Biologics, Inc.)|Forward P/E Multiple Aptevo (APVO)|Forward P/E Multiple AIM (aimimmuno.com)|Forward P/E Multiple Aditxt Corp ADTX|GRI: Projected Price to Earnings|Future Price to Earnings Multiple XRTX (xortx.com)|Vyome Holdings Inc. (HIND) - Future Price to Earnings|Indaptus Therapeutics, Inc. - Future Price to Earnings Multiple|Future Price to Earnings Scinai|Projected Price to Earnings Ratio CalciMedica, Inc. CALI|Future Price to Earnings Affimed NV (AFMD)|Forward P/E Multiple Allakos Inc (ALLK)|Future Price to Earnings hookipapharma.com HOOK|Forward P/E Multiple IGM Biosciences, Inc. IGMS|iTeos Pharma - Forward P/E Multiple|OCEA - Forward P/E Multiple|TCBP: Forward P/E Multiple|Third Harmonic Bio - Future Price to Earnings Multiple
